Back to Studies

IMPAACT 2010 / VESTED

Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants

Study Status

Participants Off Study and Primary Analysis Completed

Locality

US & Non-US

DAIDS Number

30129

IND Number

133,438

Clinical Trials Link

Summary

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a dolutegravir-containing antiretroviral regimen or an efavirenz-containing antiretroviral regimen at 14-28 weeks gestation. The VESTED study (Virologic Efficacy and Safety of ART Combinations with TAF/TDF, EFV, and DTG) will compare the regimens with regard to safety and virologic efficacy during pregnancy and through 50 weeks of maternal and infant follow-up postpartum.

IMPAACT 2010 Randomization
ARVs with EFV and DTG combinations
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...